MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

231.21 -4.98 (-2.11%)
Streaming Delayed Price Updated: 3:21 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,791,183
Open 233.42
Bid (Size) 231.11 (300)
Ask (Size) 231.31 (200)
Prev. Close 236.19
Today's Range 228.00 - 234.80
52wk Range 164.39 - 244.81
Shares Outstanding N/A
Dividend Yield 2.99%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell ↗
Having successfully navigated the Humira patent cliff, AbbVie is poised for continued growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent... 
Via Finterra
Topics Economy Initial Public Offering Retirement

Performance

YTD
+0.8%
+0.8%
1 Month
+2.5%
+2.5%
3 Month
+0.4%
+0.4%
6 Month
+9.1%
+9.1%
1 Year
+11.3%
+11.3%

More News

Read More
News headline image
Why AbbVie Stock May Be the Ultimate Option for Dividend Investors ↗
Via The Motley Fool
Topics Economy
News headline image
Where Will AbbVie Be in 5 Years? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises ↗
Via Stocktwits
Topics Intellectual Property
News headline image
This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income ↗
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
1 Cash-Producing Stock to Target This Week and 2 We Ignore
Via StockStory
News headline image
3 Stocks to Buy and Hold for 2026 and Beyond ↗
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
2 Dividend Stocks to Hold for the Next 5 Years ↗
Via The Motley Fool
Topics Energy Intellectual Property
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
6 Forever Dividend Stocks ↗
Via The Motley Fool
News headline image
1 Mega-Cap Stock on Our Watchlist and 2 We Avoid
Via StockStory
News headline image
8 Cheap Stocks to Buy in 2026 ↗
Via The Motley Fool
News headline image
1 No-Brainer Dividend Stock to Buy on the Dip ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
5 Best Stocks to Buy in February ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Dividend Stocks to Hold for the Next 20 Years ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
Via The Motley Fool
Topics Stocks
News headline image
Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗
Via The Motley Fool
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
The Great Rotation: Healthcare Emerges as the S&P 500’s New Crown Jewel in 2026
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
1 Reason I'm Never Selling AbbVie Stock ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
Via Finterra
Topics Economy Intellectual Property
News headline image
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call
Via StockStory
Topics Earnings

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 231.21
When was AbbVie last traded?
The last trade of AbbVie was at 03/05/26 03:21 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story